NOVONIX Ltd Files 6-K with Appendix 2A

Ticker: NVNXF · Form: 6-K · Filed: Dec 2, 2024 · CIK: 1859795

Sentiment: neutral

Topics: reporting, foreign-private-issuer, sec-filing

TL;DR

NOVONIX filed a 6-K with Appendix 2A, likely related to stock exchange updates.

AI Summary

NOVONIX Limited filed a Form 6-K on November 29, 2024, reporting as a foreign private issuer. The filing includes Appendix 2A, which typically relates to the admission of securities to listing and/or dealings on an exchange. The company is incorporated in Australia and has its principal executive office in Brisbane.

Why It Matters

This filing indicates potential corporate actions or updates related to NOVONIX's securities, which could impact investors' understanding of the company's status on the stock exchange.

Risk Assessment

Risk Level: low — The filing is a routine report for a foreign private issuer and does not appear to contain significant negative financial or operational news.

Key Players & Entities

FAQ

What is the purpose of the Appendix 2A included in this 6-K filing?

Appendix 2A typically relates to the admission of securities to listing and/or dealings on an exchange, suggesting NOVONIX may be providing updates or making applications related to its listed securities.

When was the period of report for this Form 6-K?

The conformed period of report for this Form 6-K was November 29, 2024.

Where is NOVONIX Limited's principal executive office located?

NOVONIX Limited's principal executive office is located at Level 38, 71 Eagle Street, Brisbane, QLD 4000, Australia.

Does NOVONIX Limited file its annual reports under Form 20-F or Form 40-F?

NOVONIX Limited indicates it files its annual reports under cover of Form 20-F.

What is the SEC file number for NOVONIX Limited?

The SEC file number for NOVONIX Limited is 001-41208.

Filing Stats: 197 words · 1 min read · ~1 pages · Grade level 13.1 · Accepted 2024-12-02 08:33:50

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NOVONIX LIMITED By: /s/ Dr. John Christopher Burns Dr. John Christopher Burns Chief Executive Officer Date: December 2, 2024

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing